Table of Contents
Executive Summary
- Modulating the immune system
- Inflammatory and Autoimmune Disorders
- Infectious disease
- Cancer
- Transplantation
- Market Considerations and Forecasts
- Trends and Opportunities
Chapter 1 Modulating the immune system
- Summary
- Introduction
- Overview of the human immune system
- Innate (non-specific) immunity
- Cytokines: the chemical messengers
- Lipid mediators of inflammation
- Phagocytic and natural killer cells
- Complement system
- Inflammatory and acute phase responses
- Adaptive (specific) immunity
- B and T lymphocytes
- Antigen-presenting cells
- Biopharmaceuticals as immunomodulators
- Delivery of biopharmaceuticals
- Regulatory requirements (US)
- Scope of this Report
Chapter 2 Inflammatory and Autoimmune Disorders
- Summary
- Introduction
- The role of T cells in autoimmune diseases and allergies
- Current therapies
- Glucocorticoids
- Nonsteroidal anti-inflammatory drugs
- Nitric oxide (NO)-releasing NSAIDs
- Therapies targeting proinflammatory cytokines
- B cell-targeted therapeutics
- Other therapies
- Current drug targets
- GPCRs
- Chemokine receptors
- LTB4 receptor
- S1P1 receptor
- Leukocyte surface antigens
- Cytokines and their receptors
- IL-1 and receptors
- Other ILs and receptors
- TNF proteins and receptors
- BlyS (BAFF) and APRIL
- Interferons
- Other cytokines
- Kinases
- Other targets
- Immunomodulators in clinical development (US)
- Rheumatoid arthritis
- Psoriasis
- Multiple sclerosis
- Inflammatory bowel disease
- Systemic lupus erythematosus
- Asthma and allergic rhinitis
- Chronic obstructive pulmonary disease
- Cardiovascular disease
Chapter 3 Infectious Disease
- Summary
- Introduction
- Types of vaccines
- Combination vaccines
- Viruses
- Influenza
- HIV
- New vaccines
- Other immunotherapies
- Hepatitis viruses
- New vaccines
- Other immunotherapies
- Herpes simplex viruses
- RSV
- New vaccines and immunotherapies
- Bacteria, fungi and parasites
- New vaccines
- Other immuotherapies
Chapter 4 Cancer
- Summary
- Overview of Cancer
- Tumor immunity
- Treatment of cancer
- Overview of immunotherapies
- Small molecule immunomodulators
- Cytokines
- Monoclonal antibodies
- Recent trends
- Prophylactic vaccines
- Therapeutic vaccines
- Tumor antigens targeted by vaccines
- Antigen/adjuvant vaccines
- Whole cell vaccines
- Dendritic cell vaccines
- Idiotype vaccines
- Genetically-engineered vaccines
- Immunostimulatory sequences
- Adoptive T cell immunity
Chapter 5 Transplantation
- Summary
- Introduction to organ transplantation
- Rejection mechanisms
- Prevention of rejection
- Small molecule immunosuppressants
- Calcineurin inhibitors
- Anti-proliferatives
- Glucocorticoids
- mTOR inhibitors
- Novel small molecule drugs
- Induction therapy with T cell antibodies
- Polyclonal antibodies
- Monoclonal antibodies and fusion proteins
- Co-stimulatory blockers
- New approaches to prevention of GVHD
Chapter 6 Market Considerations and Forecasts
- Summary
- Introduction
- Overview of the AIID Market
- Rheumatoid arthritis
- Multiple sclerosis
- Inflammatory bowel disease
- Systemic lupus erythematosus
- Psoriasis
- Asthma and allergic rhinitis
- Overview of the Viral Infectious Disease Market
- Influenza
- HIV
- Hepatitis viruses
- Herpes simplex viruses
- RSV
- Overview of the Cancer Market
- Cytokines
- Monoclonal antibodies
- Prophylactic vaccines
- Therapeutic vaccines
- Overview of the Transplantation Market
- Quantitative Market Analysis
- The global pharmaceutical market
- The global immunomodulator market
- Immunosuppression in AIID and allergies
- Vaccines for viral pathogens
- Vaccines for cancer
- Monoclonal antibodies for cancer
- Recombinant interferons
- Transplantation medicine
- Geographical analysis
Chapter 7 Trends and Opportunities
- Summary
- Preclinical immunomodulator programs
- Trends in vaccines
- Trends in monoclonal antibodies
- Future players in immunomodulation
- Immunomodulators Patent Survey
- Patenting Activity
- Leading assignees
- Patent citation analysis
Appendix
- Research Methodology
- Index
List of Figures
- Figure 7.1: Immunomodulators - Drug origins
List of Tables
- Table 1.1: Immunomodulators Summary
- Table 1.2: Indications by Category and Within-Category Count
- Table 1.3: Recent Immunomodulator Deals
- Table 2.4: Immunomodulators in US Clinical Development (Rheumatoid
Arthritis)
- Table 2.5: Immunomodulators in US Clinical Development (Psoriasis)
- Table 2.6: Immunomodulators in US Clinical Development (Multiple Sclerosis)
- Table 2.7: Immunomodulators in US Clinical Development (Crohn' s Disease)
- Table 2.8: Immunomodulators in US Clinical Development (Ulcerative Colitis)
- Table 2.9: Immunomodulators in US Clinical Development (SLE)
- Table 2.10: Immunomodulators in US Clinical Development (Asthma)
- Table 2.11: Immunomodulators in US Clinical Development (Allergic Rhinitis)
- Table 2.12: Immunomodulators in US Clinical Development (COPD)
- Table 2.13: Immunomodulators in US Clinical Development (General
Inflammation)
- Table 2.14: Immunomodulators in US Clinical Development (Autoimmune
Disorders)
- Table 3.15: Immunomodulators in US Clinical Development (Influenza)
- Table 3.16: Immunomodulators in US Clinical Development (HIV)
- Table 3.17: Immunomodulators in US Clinical Development (Viral Hepatitis)
- Table 3.18: Immunomodulators in US Clinical Development (Herpes simplex)
- Table 3.19: Immunomodulators in US Clinical Development (Other Viruses)
- Table 3.20: Immunomodulators in US Clinical Development (Bacteria, Fungi,
and Parasites)
- Table 4.21: Immunomodulators in US Clinical Development (Breast cancer)
- Table 4.22: Immunomodulators in US Clinical Development (Prostate cancer)
- Table 4.23: Immunomodulators in US Clinical Development (Non-Small Cell
Lung Cancer)
- Table 4.24: Immunomodulators in US Clinical Development (Ovarian cancer)
- Table 4.25: Immunomodulators in US Clinical Development (Malignant
melanoma)
- Table 4.26: Immunomodulators in US Clinical Development (Head and neck
cancer)
- Table 4.27: Immunomodulators in US Clinical Development (Pancreatic cancer)
- Table 4.28: Immunomodulators in US Clinical Development (Renal cancer)
- Table 4.29: Immunomodulators in US Clinical Development (Solid tumours)
- Table 4.30: Immunomodulators in US Clinical Development (Lymphoma)
- Table 4.31: Immunomodulators in US Clinical Development (Non-Hodgkin' s
Lymphoma)
- Table 4.32: Immunomodulators in US Clinical Development (Multiple myeloma)
- Table 4.33: Immunomodulators in US Clinical Development (General Cancer)
- Table 4.34: Immunomodulators in US Clinical Development (Colorectal cancer)
- Table 4.35: Immunomodulators in US Clinical Development (Chronic
Lymphocytic Leukaemia)
- Table 4.36: Glossary - Immunomodulators in US Clinical Development
- Table 5.37: Immunomodulators in US Clinical Development (Transplantation)
- Table 6.38: World Population Data (2006)
- Table 6.39: Inflammatory Disease Prevalences and Incidences (2006)
- Table 6.40: Inflammatory Disease Summary (2006)
- Table 6.41: World AIDS Statistics (2006)
- Table 6.42: World Annual Cancer Incidence by Site (2002)
- Table 6.43: Trends in cancer incidence, 1975-2000
- Table 6.44: World Cancer Statistics (2002)
- Table 6.45: World Pharma Market by Therapeutic Category, 2006-2011
- Table 6.46: World Pharma Market by Region, 2006-2011
- Table 6.47: Immunomodulator Analysis by Therapy Type (2006-2011)
- Table 6.48: Immunomodulator Analysis by Indication (2006-2011)
- Table 6.49: World Immunomodulator Market by Region, 2006-2011
- Table 7.50: Preclinical Immunomodulators by Indication
- Table 7.51: Preclinical Vaccines: Therapy Types
- Table 7.52: Preclinical Vaccines: Top Indications
- Table 7.53: Monoclonal antibodies in preclinical development
- Table 7.54: Preclinical Immunomodulators: Top Originators
- Table 7.55: Preclinical Vaccines: Top Originators
- Table 7.56: Immunomodulator Patent Survey: Category Definitions
- Table 7.57: Summary of Patents by Segment
- Table 7.58: US Immunomodulator Patents: Filing and Publication Activity,
1992-2007 (All Patents)
- Table 7.59: US Immunomodulator Patents: Filing and Publication Activity,
1992-2007 (Autoimmunity)
- Table 7.60: US Immunomodulator Patents: Filing and Publication Activity,
1992-2007 (Allergy)
- Table 7.61: US Immunomodulator Patents: Filing and Publication Activity,
1992-2007 (General Immunotherapy)
- Table 7.62: US Immunomodulator Patents: Filing and Publication Activity,
1992-2007 (Transplantation)
- Table 7.63: US Immunomodulator Patents: Filing and Publication Activity,
1992-2007 (Vaccines)
- Table 7.64: US Immunomodulator Patents: Assignee Summary
- Table 7.65: US Immunomodulator Patents: Top Assignees
- Table 7.66: US Immunomodulator Patents: Most Frequenty Cited Organizations
- Table 7.67: Top-Cited Immunomodulator Patents, Entire Data Set (US
Filings, 1992-2007)
|
Related Report
|
View Cart
